AI to be used as primary tool in diagnosing breast cancer in pilot program
Early and accurate detection of breast cancer is critical for effective treatment and saving women's lives.
By Hannah Brown, Jerusalem Post, December 16, 2020
 |
The Galen Breast AI solution (photo credit: IBEX MEDICAL ANALYTICS) |
Ibex Medical Analytics, a pioneer in artificial intelligence
(AI)-based cancer diagnostics, and KSM, the Research and Innovation
Center of Maccabi Healthcare Services – one of Israel’s largest HMOs –
announced an innovative pilot of Ibex’s Galen Breast solution for
AI-powered primary diagnosis of breast cancer at Maccabi’s Pathology
Institute on Wednesday.
The
pilot at Maccabi’s Pathology Institute includes 2,000 breast biopsies
on which pathologists will use Galen Breast as a “first read”
application. It is the first-ever deployment of an AI application for
primary diagnosis of breast cancer.
Breast cancer
is the most common malignant disease in women worldwide, with over 2
million new cases each year. Early and accurate detection is critical
for effective treatment and saving women’s lives.
During
the pilot, all breast biopsies examined at Maccabi will be digitized
using a digital pathology scanner, and automatically analyzed by the
Galen Breast solution prior to review by a pathologist. The solution
detects suspicious findings on biopsies, such as regions with high
probability of including cancer cells, and classifies them to one of
three risk levels, ranging from high risk of cancer to benign.
The Galen
Breast First Read is designed to help pathologists diagnose breast
biopsies more accurately, more efficiently, and at a considerably faster
turnaround time compared to diagnoses on a microscope.
 |
| Breast cancer detected by Ibex’s Galen Breast AI solution - the tumor is marked with a heatmap. (Credit: Ibex) |
Ibex’s AI solution has been used at Maccabi’s Pathology Institute since
2018, and already today, all breast and prostate biopsies undergo
AI-based second read, supporting improved accuracy and quality control.
The solution alerts when discrepancies between the pathologist’s
diagnosis and the AI algorithm’s findings are detected, thus providing a
safety net in case of error or misdiagnosis.
“We are proud to use AI as an integral part of breast cancer
diagnosis,” said Judith Sandbank, MD and director of the Pathology
Institute at Maccabi. “We have already had a successful experience with
Ibex’s AI solution, enabling us to implement quality control and perform
second read on biopsies, and now we are making a significant leap
forward with the integration of AI into primary cancer diagnosis.”
“Artificial
intelligence is revolutionizing healthcare, and its integration into
clinical practice will significantly improve the ability to diagnose
cancer quickly and efficiently,” said Dr. Chaim Linhart, co-founder and
chief technology officer of Ibex.
“Our solutions are used in routine practice in pathology laboratories worldwide, and have already helped detect breast and prostate cancers that were misdiagnosed by pathologists as benign. It is now time to take AI to the next level and employ its capabilities across a broader range of the diagnostic workflow.”
Future expansions of the pilot will aim to include other healthcare providers.
Neander-Troll says :Be sure to recommend and follow Chucks " Life of Earth " Blog at:
https://disqus.com/home/forum/lifeofearth/
No comments:
Post a Comment